trial to prevent kidney injury due to side effects of the treatment to prevent rejection of a transplanted lung.

Phase 1

• Conditions: kidney damage in ciclosporin treated lung transplant patients.; MedDRA version: 14.1Level: PTClassification code 10029155Term: Nephropathy toxicSystem Organ Class: 10038359 - Renal and urinary disorders; MedDRA version: 14.1Level: PTClassification code 10056409Term: Heart and lung transplantSystem Organ Class: 10042613 - Surgical and medical procedures; MedDRA version: 14.1Level: PTClassification code 10025127Term: Lung transplantSystem Organ Class: 10042613 - Surgical and medical procedures; Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]

• Registration Number: EUCTR2008-004771-22-DK
• Lead Sponsor: Rigshospitalet, Kardiologisk afd

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2008-07-29
• Last Update Posted: 17 October 2016

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Patients over the age of 18 and eligible for a lung transplant

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 60
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Patients are excluded if:
Treated with calcium channel blocker within 14 days
Women in the child bearing age who are not using safe contraception
Allgies towoards felodipin

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified